TScan Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 4, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 4, 2026
TCRX$0.19+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Year EndedDecember 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue | ||
| Collaboration and license revenue | $10,325 | $2,816 |
| Operating expenses: | ||
| Research and development | 114,150 | 107,350 |
| General and administrative | 31,988 | 30,287 |
| Total operating expenses | 146,138 | 137,637 |
| Loss from operations | (135,813) | (134,821) |
| Other (expense) income: | ||
| Interest and other income, net | 8,816 | 12,065 |
| Interest expense | (2,769) | (3,653) |
| Loss on extinguishment of debt | - | (1,090) |
| Total other income | 6,047 | 7,322 |
| Net loss | $(129,766) | $(127,499) |
| Net loss per share, basic and diluted | $(1.00) | $(1.14) |
| Weighted average common shares outstanding—basic and diluted | 129,777,415 | 111,990,417 |
| Comprehensive loss: | ||
| Net loss | $(129,766) | $(127,499) |
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on available-for-sale securities | (51) | 51 |
| Comprehensive loss | $(129,817) | $(127,448) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.